Shots:

• The CHRYSALIS study involves assessing amivantamab as a monothx. and in combination with Lazertinib in 460 patients with advanced NSCLC with various EGFR mutations
• The updated data showed mDOR of 9.6mos. in CT-naïve patients with NSCLC & EGFR exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib. These results led to new studies evaluating the combination regimen in the P-III MARIPOSA study and P-I/Ib CHRYSALIS-2 study
• The findings will be presented at the ASCO. Additionally- Janssen will present data comparing amivantamab monotherapy and real-world therapies in the same population

  Ref: PR Newswire | Image: Janssen